Press Releases

Press Releases

Samsung Biologics Names John Rim as President and CEO

Samsung Biologics announced John Rim as its President and CEO. The appointment was made effective immediately and formalized via the company’s board of directors meeting today.

Prior to being appointed CEO, John served as EVP at Samsung Biologics for the past three years and was a key senior leadership contributor in driving the company’s success through a strong focus on client satisfaction and global business acumen. John was also instrumental in rapidly expanding the manufacturing portfolio across Samsung Biologics and for the continuous operational excellence in Plant 3, the world’s largest manufacturing capacity at a single site. As CEO, John will continue to serve on the company’s board as an inside director offering his in-depth industry experience and global background.

Prior to joining Samsung Biologics in 2018, John worked for Genentech/Roche in a variety of senior global leadership roles in Technical Operations, Product Development, and Research and Development in the US and Europe. John has also held senior leadership roles with Astellas Pharmaceuticals in General Management, Sales & Marketing, Technical Operations, Customer Service, Business Development, and Strategic Planning. John has over 30 years’ experience in the biopharmaceutical industry and began his career as a management consultant with Booz, Allen & Hamilton consulting to pharmaceutical companies in the US and Europe.  

“I am deeply grateful and excited by the opportunity to lead Samsung Biologics into the next decade,” said John Rim, CEO of Samsung Biologics. “This is an extraordinary company, unparalleled in its phenomenal growth and dedication to client satisfaction, made possible by the company’s unrelenting vision and passion, and business ution by great people whom I will have the privilege to lead as CEO.”

Samsung Biologics has shown strong performance throughout the year with a continuous increase in sales volume across all plants, stable business and supply management, and global business expansion including the opening of its first US CDO R&D Center in San Francisco. The company also recently commenced construction of its fourth plant, which is expected to further boost the company’s competitiveness in serving the growing global demand for CDMO scale and flexibility.

Samsung Biologics announced John Rim as its President and CEO. The appointment was made effective immediately and formalized via the company’s board of directors meeting today.

Prior to being appointed CEO, John served as EVP at Samsung Biologics for the past three years and was a key senior leadership contributor in driving the company’s success through a strong focus on client satisfaction and global business acumen. John was also instrumental in rapidly expanding the manufacturing portfolio across Samsung Biologics and for the continuous operational excellence in Plant 3, the world’s largest manufacturing capacity at a single site. As CEO, John will continue to serve on the company’s board as an inside director offering his in-depth industry experience and global background.

Prior to joining Samsung Biologics in 2018, John worked for Genentech/Roche in a variety of senior global leadership roles in Technical Operations, Product Development, and Research and Development in the US and Europe. John has also held senior leadership roles with Astellas Pharmaceuticals in General Management, Sales & Marketing, Technical Operations, Customer Service, Business Development, and Strategic Planning. John has over 30 years’ experience in the biopharmaceutical industry and began his career as a management consultant with Booz, Allen & Hamilton consulting to pharmaceutical companies in the US and Europe.  

“I am deeply grateful and excited by the opportunity to lead Samsung Biologics into the next decade,” said John Rim, CEO of Samsung Biologics. “This is an extraordinary company, unparalleled in its phenomenal growth and dedication to client satisfaction, made possible by the company’s unrelenting vision and passion, and business ution by great people whom I will have the privilege to lead as CEO.”

Samsung Biologics has shown strong performance throughout the year with a continuous increase in sales volume across all plants, stable business and supply management, and global business expansion including the opening of its first US CDO R&D Center in San Francisco. The company also recently commenced construction of its fourth plant, which is expected to further boost the company’s competitiveness in serving the growing global demand for CDMO scale and flexibility.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION